Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

This is the first of a two-case series (106-059-1 and 306-207-1). This case is situated in the chemical and pharmaceutical industry and deals with the ongoing restructuring at Bayer AG, which resulted in the separation of most of the company''s chemical activities and about one third of its polymer operations into an independent publicly-traded company Lanxess AG. Bayer was pressured by financial markets and needed to change its strategy in the light of decreasing stock value. Furthermore the case serves as the prelude for the case Lanxess AG (B), which presents in more depth the financial background and the rationale for different options to realise such a separation. A teaching note supplement (306-207-9) is available to accompany the teaching note.
Location:
Industry:
Size:
75,000 employees
Other setting(s):
2003

About

Abstract

This is the first of a two-case series (106-059-1 and 306-207-1). This case is situated in the chemical and pharmaceutical industry and deals with the ongoing restructuring at Bayer AG, which resulted in the separation of most of the company''s chemical activities and about one third of its polymer operations into an independent publicly-traded company Lanxess AG. Bayer was pressured by financial markets and needed to change its strategy in the light of decreasing stock value. Furthermore the case serves as the prelude for the case Lanxess AG (B), which presents in more depth the financial background and the rationale for different options to realise such a separation. A teaching note supplement (306-207-9) is available to accompany the teaching note.

Settings

Location:
Industry:
Size:
75,000 employees
Other setting(s):
2003

Related